Engineered t cells take aim at hard-to-treat prostate cancer
NCT ID NCT02744287
First seen Feb 26, 2026 · Last updated May 23, 2026 · Updated 11 times
Summary
This early-stage study tested a new treatment called BPX-601 for people with advanced prostate cancer that had stopped responding to other therapies. The treatment uses a patient's own immune cells, modified to recognize and attack cancer cells carrying a specific marker (PSCA). The main goals were to check safety and find the right dose. The study was terminated early, but results help guide future research.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Baylor Sammons Cancer Center
Dallas, Texas, 75246, United States
-
Columbia University Medical Center
New York, New York, 10032, United States
-
Duke University
Durham, North Carolina, 27705, United States
-
Emory Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
John Theurer Cancer Center, Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
-
Rush University Medical Center
Chicago, Illinois, 60612, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
-
University of Chicago Medicine
Chicago, Illinois, 60637, United States
-
University of Nebraska
Omaha, Nebraska, 68198, United States
Conditions
Explore the condition pages connected to this study.